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AMR   antibody-mediated rejection 
ARR   acute reversible rejection 
AUC   area under curve 
BMI   body mass index 
CDC   complement-mediated lymphocytotoxicity test 
CDCXM  complement-mediated lymphocytotoxicity crossmatch 
CI   confidence interval 
CIT   cold ischemia time 
CPRA   calculated PRA 
DGF   delayed graft function 
DSA   donor-specific HLA antibodies 
DTT   dithiothreitol 
EDTA   ethylenediaminetetraacetic acid 
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IF/TA   interstitial fibrosis and tubular atrophy 
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MHC   major histocompatibility complex 
OR   odds ratio 
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PRA   panel reactive antibody 
ROC   receiver operating characteristic 
RR   relative risk 
RRT   renal replacement therapy 
RTx   renal transplantation 
SBT   Sanger sequencing 
SRR   steroid-resistant rejection 
SSO   sequence-specific oligonucleotide probes 









Renal transplantation is a preferred choice of treatment for patients who have lost 
their kidney function due to end-stage renal disease (ESRD). Transplantations in 
Finland have been centralized to Helsinki University Hospital for both paediatric 
and adult patients. The results of the kidney transplantation program in Finland 
have improved over the years and are now excellent, with a one-year graft survival 
of over 90 %. The major improvements concern short-term problems, and the main 
challenge today is chronic rejection and long-term survival. The key to further 
improvements is prevention of chronic rejection and the adequate level of 
immunosuppression. 
 
This thesis was designed to study the prevalence of human leukocyte antigen 
(HLA) antibodies and to evaluate the relevance of identified donor-specific 
antibodies (DSA) in the graft outcome. The focus was on graft function, as assessed 
by the glomerular filtration rate (GFR) and occurrence of delayed graft function 
(DGF). Another goal for this study was to evaluate various techniques for 
measuring the immunisation status of a patient and the sensitivity and specificity 
of different crossmatch techniques with the aim of developing practices in 
histocompatibility testing. 
 
Several cohorts were used in this study. HLA allele frequency, haplotype and panel 
reactive antibody (PRA) calculations included the data provided by the Finnish 
Bone Marrow Donor Registry (19807 individuals) and the Finnish Cord Blood 
Bank (2699 individuals). In addition, 30 immunised patients were included. A total 
of 235 patients waiting for kidney transplant and 40 deceased donors were used in 
the prediction of crossmatch outcome. Retrospective clinical studies included 123 
pediatric and 771 adult kidney transplant patients. 
 
In our study of the Finnish population, a limited amount of allelic diversity was 
found. For many HLA antigens, practically only one allele is identified. For 
example, it is extremely unlikely that A3, A11 and A24 are found to be alleles other 
than A*03:01, A*11:01 or A*24:02, respectively. Also, the most common Finnish 
HLA haplotypes have very high frequencies when compared to other populations 
and some haplotypes are unique to the Finnish population. In virtual PRA, HLA 
antibodies identified against all potential donors were assessed and reported as a 




that the patient is immunised against. Due to the uniqueness of the Finnish HLA 
composition, the use of a calculated population-specific PRA provides a more 
accurate and reliable estimate of the level of immunisation against available 
donors 
 
Three different crossmatch methods were compared against virtual crossmatch 
(VXM) results. The flow cytometric crossmatch (FCXM) and Luminex crossmatch 
(LXM) proved to be the most accurate methods according to the receiver operating 
characteristic (ROC) analysis, with area under curve (AUC) values of 0.861 and 
0.805, respectively. The performance of the complement-mediated 
lymphocytotoxicity crossmatch (CDCXM) was not as good (AUC: 0.724). There was 
no clear correlation between the serum samples providing false positive and 
negative results in each crossmatch technique, which indicates that the main 
reason for the differences is that each method identifies a different type of 
antibodies. 
 
In the pediatric cohort, HLA antibodies were detected in half of the samples. 
During the follow-up, one third of the patients presented antibodies against the 
transplanted kidney. We did not find any association between DSA and poor GFR 
at the time of sampling or later during the follow-up. 
 
In the adult cohort one third (265/771) of the patients were immunised. DSA was 
detected in 13% (103/771) of the patients at the time of transplantation, even with 
a negative CDCXM. DGF was more common in patients with DSA than in non-
immunised patients (48% and 26%, respectively). DSA against all loci contributed 
a risk for DGF, but DRB1 seemed to provide the highest relative risk (RR) 
individually (RR 2.4). Also, the number of DSA and the strength of DSA as 









The human kidneys are a pair of organs situated at the back of the abdominal 
cavity. The role of the kidneys is to excrete soluble waste and regulate body fluids, 
electrolytes and acid-base balance and to produce hormones. When kidney function 
is lost due to ESRD, renal replacement therapy (RRT) is needed. For this, there 
are two options: dialysis or renal transplantation (RTx). As RTx improves both 
quality of life and life expectancy compared to dialysis, it is therefore the preferred 
form of treatment (Tennankore et al. 2014). The first kidney transplantation in 
Finland was performed in 1964 (Salmela et al. 2004). In recent years, the average 
annual rate has been 250 transplantations (Scandiatransplant 2017). The number 
of pediatric RTx is approximately ten to twenty per year (Salmela et al. 2004). 
 
The assessment of histocompatibility has played a critical role in RTx allocation 
since the beginning. Ideally, the recipient and the kidney donor harbor similar 
tissue types, in other words are HLA identical. As this is rarely achievable due to 
the wide variety of possible HLA combinations and the limited number of 
transplants, mismatching must be tolerated. The key to successful RTx is to use 
transplants with accepted immunological mismatches and avoid the ones with 
unfavorable outcome (Claas et al. 2004).  
 
In addition to the blood group barrier, immunisation against foreign HLA is one of 
the greatest obstacles to receive a transplant with a good prognosis. Laboratory 
techniques for assessing the preformed humoral immunity of the recipients in the 
terms of its capability to damage the potential transplant have been used since the 
beginning of transplantation (Patel and Terasaki 1969).  
 
CDCXM has been the gold standard in the detection of preformed donor-directed 
HLA antibodies (Graff et al. 2010). Although CDCXM enables the identification of 
a compatible donor for a patient and ensures safe transplant, it has some 
drawbacks, and therefore other crossmatch methods utilizing different 
technologies, e.g. flow cytometry and bead array, have been developed (Ho et al. 
2008). As it is not possible to perform crossmatch between a donor and all potential 
recipients, a pre-selection of most suitable recipients is necessary. This is done 




Patients waiting for a transplant are screened regularly for HLA antibodies. 
Today, bead array is the preferred method to screen pre-existing HLA antibodies 
from the patient sera (Minucci et al. 2017). Predetermined antibody specificities 
allow virtual crossmatching to be performed as soon as the donor candidate has 
been typed for HLA. Prediction of a crossmatch test result based on HLA 
antibodies identified with solid phase assays is not optimal as the sensitivity of 
these methods is very different (Eng et al. 2008; Wahrmann et al. 2013). 
 
The current practice in Finland is to perform CDCXM-negative transplantations 
without VXM assessment, except when the patient is prioritized due to high 
immunisation level. The value of VXM, however, is under debate as many of the 
patients with pre-formed HLA antibodies against the graft, have acceptable 
transplant outcome after all (Gupta et al. 2008). The challenge is to identify 
preformed DSA with clinical relevance. Pretransplant DSA have been reported to 
associate with several clinical complications such as antibody-mediated rejection, 
graft loss and DGF (Caro-Oleas et al. 2012a; Gilbert et al. 2011; Willicombe et al. 







5 REVIEW OF THE LITERATURE 
 
 
5.1 Renal transplantation 
 
RTx is the best treatment for patients with ESRD. Both the life expectancy and 
quality of life of transplanted patients is better than for patients remaining on 
dialysis (Lloveras et al. 2015; Tennankore et al. 2014). The incidence of Finnish 
patients in RRT was 84 per million population (total n=461) in 2014 (Pippias et al. 
2017). This was the lowest incidence in the Nordic countries, while in Europe as a 
whole, the incidence was 133 per million population.  
 
The kidney diseases leading to ESRD differ in adults and children. In Finland, the 
most common diseases in adults, are diabetic kidney disease, glomerulonephritis, 
polycystic kidney disease, and nephrosclerosis (Finnish registry for kidney 
diseases 2016). For children, the most common causes are congenital nephrotic 
syndrome of the Finnish type, other hereditary kidney diseases, and congenital 
urological anomalies (Holmberg and Jalanko 2016). The graft survival of 
transplanted kidneys has improved over the years (Collaborative transplant study 








Figure 1.  Graft survival according to transplantation year in Europe. Reproduced 
with permission from the publisher (Collaborative transplant study 2017). 
 
 
5.2 Transplantation immunology 
 
 
5.2.1 Human leukocyte antigens 
 
HLA complex is located in the chromosome 6p21.3 and it encodes major 
histocompatibility complex (MHC) proteins. With more than 17,000 alleles 
identified, the HLA genes are highly polymorphic (Robinson et al. 2015). Classical 
HLA molecules are divided into class I and class II molecules. HLA class I 
molecules (HLA-A, -B, -C) are heterodimers formed by two subunits: the 
membrane bound α chain encoded by the HLA gene and the non-polymorphic β2-
micglobulin that stabilizes the structure. HLA class II molecules (DR, DQ, DP) are 
heterodimers formed by two transmembrane chains, α and β (Fig. 2). These chains 
are encoded by separate HLA genes, with DRA1, DQA1, DPA1 encoding α chains 
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and DRB1, DRB3, DRB4, DRB5, DQB1, DPB1 encoding β chains. There is a strong 
linkage disequilibrium in the HLA complex and the entire HLA complex is usually 
inherited as a haplotype. With a low recombination frequency, some allelic 






Figure 2. Structure of HLA molecules. The HLA class I molecule is a heterodimer formed 
by the α chain and the non-polymorphic β2-microglobulin. The peptide binding 
groove of the HLA class I molecules is formed by α1 and α2 domains. The HLA 
class II molecule is a heterodimer of α and β chains. The peptide binding groove 




HLA class I and II differ in their expression. Class I molecules are expressed on 
the cell surface of all nucleated cells whereas class II molecules are expressed only 
in antigen presenting cells such as dendritic cells, macrophages, activated T cells, 
and B cells. The role of HLA molecules is to present peptides to T lymphocytes. 
HLA class I molecules present peptides derived from degraded intracellular 
proteins of the cell. These include self-peptides and peptides derived from viral 
infection. HLA class II molecules present peptides derived from extracellular 
proteins that are endocytosed into the cell. These extracellular proteins can be 
derived from extracellular pathogens, e.g. from bacterial infection. Presentation of 
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peptides to T cells is required for the activation of adaptive immune response 
(Klein and Sato 2000). The repertoire of peptides presented by each HLA molecule 
depends on the structural properties of the peptide binding groove of each allelic 
variant. Each HLA molecule has the capability to present all peptides fulfilling the 
peptide binding pocket’s criteria related to structural, electrostatic, 






HLA molecules contribute to individuals’ ability to distinguish their own tissues 
from foreign tissue. There are two main forms of allorecognition, direct and 
indirect (Marino, Paster, Benichou 2016). In direct allorecognition, transplanted 
donor-derived HLA-peptide complexes presented by donor dendritic cells are 
directly recognized by the T cells of the recipient, leading to a response against the 
cells expressing the foreign molecule complex. This response may be formed 
against the allopeptide presented by the foreign HLA or the foreign HLA molecule 
itself (Boardman et al. 2016). In indirect allorecognition, allopeptides from the 
transplant are presented by the recipient’s own antigen presenting cells (Benichou 
and Thomson 2009). The direct pathway has been considered more important in 
rejection. However, the direct alloresponse weakens gradually, possibly due to the 
tolerogenic properties of alloantigen presentation by the parenchymal cells of the 
transplant. In contrast, the indirect pathway is expected to be permanently active, 




5.2.3 HLA antibodies 
 
The primary cause of antibody formation is exposure to foreign HLA antigens as a 
result of pregnancy, blood transfusion, or organ transplantation (Table 1). When 
antibodies were measured by bead array (Luminex), subjects without known 
immunisation events had a positive HLA-antibody rate of 12.3%, while patients 
with a history of blood transfusion, pregnancy or transplantation showed an 
immunisation rate of 22.8%, 53.1% and 88.5%, respectively; antibodies induced by 
previous transplantation or pregnancy produced higher mean fluorescence 
intensity (MFI) values than antibodies induced by transfusion (Lopes et al. 2015). 
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In addition, antibodies induced primarily by pregnancy exhibit significantly 
stronger response against restimulation by the new graft than antibodies induced 
by previous transplant or transfusion (Higgins et al. 2015).  
 
 
Table 1. Predictors of allosensitisation 
 
  OR 95% CI P Value 
Age 1.011 0.991–1.031 0.29 
Female sex 3.633 1.904–6.932 <0.001 
Sensitisation    
   None reference   
   Pregnancy only 2.702 1.243–5.874 0.012 
   Transfusion only  1.973 1.121–3.472 0.018 
   Transplantation only 60.084 23.338–156.684 <0.001 
OR, Odds ratio; CI, confidence interval (Lopes et al. 2015). 
 
Antibody formation is a result of a cascade where foreign cells shed alloantigens, 
including soluble HLA molecules. B cells of the recipient have membrane bound 
antibodies on their surface that act as B cell receptors (BCR) for extracellular 
(donor) antigens. Alloantigens are gathered through B cell receptor-mediated 
uptake (Valenzuela, Hickey, Reed 2016). Then, the activated host B cells present 
allogenic peptides using the HLA class II molecules on their cell surface to 
associated T cells that recognize the MHC peptide complex through their T cell 
receptor. Interaction between CD40 ligand and CD28 on T cells and CD40 and 
CD80/86 on B cells, combined with the production of several cytokines, facilitates 
differentiation of both T cells and B cells into effector and memory subsets 
(Karahan, Claas, Heidt 2017). While T cells can become activated as effector cells 
or differentiate into memory T cells, B cells convert to antibody-producing plasma 
cells and memory B cells (El-Awar, Jucaud, Nguyen 2017; Karahan, Claas, Heidt 










Figure 3. Antibody production. Alloantigens gathered through B cell receptor-mediated 
uptake are processed and then presented by HLA class II molecules. T cells 
recognize the MHC peptide complex through their T cell receptor. Costimulatory 
factors and cytokines enable the activation of T cells and differentiation of B cells 




The structure in the HLA molecule that is recognized by an antibody is called 
epitope (Fuller et al. 1990). This three-dimensional structure can be public, 
meaning that it is common for different HLA antigens or alleles. A good example 
of a public epitope is Bw4, which is present in half of the HLA B molecules and in 
some HLA A molecules. Other epitopes are private, meaning that they are found 
only in one antigen or one allele (El-Awar, Jucaud, Nguyen 2017). The broadness 
of the immunization largely depends on whether the target of an alloantibody is a 
public or private epitope.  
 
The antibodies formed can be of different immunoglobulin classes, of which IgM 
and IgG are of importance primarily in organ transplantation. While IgM 
antibodies are considered irrelevant for the survival of the graft (Everly et al. 
2014), they are not irrelevant in the activities of a histocompatibility laboratory as 
special measures must be taken to exclude them from various tests, such as 
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complement-mediated cytotoxicity and bead array tests. It is the IgG antibodies 
that mediate the destructive effect of immunisation and most antibody screening 
techniques measure the anti HLA IgG antibodies. Successive IgG subclass 
switching takes place during the progression of antibody production, typically from 
IgG3 to IgG1 to IgG2 to IgG4 (van Zelm 2014). Not all IgG antibodies are equal. It 
has been shown that complement-binding subtypes of IgG antibodies cause most 
of the problems in organ transplantation. IgG3 shows the strongest complement-
binding capacity, followed by IgG1. While IgG2 activates complement only weakly, 
and IgG4 does not activate complement at all, both of these subclasses are able to 
recruit effector cells through the Fc receptor (Zhang 2017). 
 
 
5.2.4 Histocompatibility in renal transplantation 
 
The immunological assessment of a donor and potential recipients consists of three 
major components. The first of these is based on ABO blood group matching. In 
Finland, ABO compatibility is required for deceased donor transplants. Secondly, 
histocompatibility of the recipient and the donor is determined at the level of 
shared HLA antigens. In RTx, this is usually determined by the shared HLA-A, -
B and -DRBI antigens. Patients fulfilling the criteria set for a sufficient HLA 
match (or prioritized by clinical parameters) will proceed to a prospective 
crossmatch, in which the presence of preformed antibodies against the donor cells 
is determined. This is crucial as compatibility between recipient and donor is 
rarely a full match due to the high level of polymorphism at the HLA. Therefore, 
preformed HLA antibodies are considered as a part of histocompatibility 
assessment with crossmatching.  
 
In addition to the standard protocol, based on ABO-compatibility, HLA-A, -B, -
DRB1 matching and crossmatching, there are other protocols, especially for highly 
immunised patients, such as the Scandiatransplant acceptable mismatch program 
(Koefoed-Nielsen et al. 2017). This program utilizesinformation on routinely 









Even with all efforts made to achieve good histocompatibility between recipients 
and donors, the immune system recognizes the new kidney as foreign tissue and 
initiates a response to destroy it, unless prevented from doing so by 
immunosuppressive medication. Immunosuppressive drugs lower the ability of the 
immune system to reject a transplanted organ. Immunosuppressive drugs are 
classified into several categories: calcineurin inhibitors, antiproliferative agents, 
corticosteroids, and targeted antibodies. Most of these drugs are targeted against 
T cell function. Calcineurin inhibitors prevent the release of calcineurin and 
interleukin-2 transcription; mycophenolic acid prevents purine (nucleotide) 
synthesis; inhibitors of the mammalian target of rapamycin induce cell cycle arrest 
in T cells; azathioprine inhibits DNA synthesis; and steroids inhibit transcription 
of inflammatory cytokines, while monoclonal and polyclonal antibodies have a 
range of targets (Lim, Kohli, Bloom 2017). In addition to the desired properties, 
immunosuppressive drugs have many side-effects, such as nephro toxicity, 
dyslipidemia, glucose intolerance, and increased risk for infections and cancer 
(Halloran 2004). Usually combination therapy allowing reduced doses of individual 





The process leading to rejection involves three stages: 1. Recognition of the 
transplant as non-self, 2. Generation of immune response, 3. Destruction of 
transplanted organ (Becker, Morath, Suesal 2016). The underlying mechanism in 
rejection can be either T cell-mediated or antibody-mediated. Rejections can be 
classified according to timing and histological findings into hyperacute (minutes to 
hours), acute (days to months), and chronic (months to years) (Mehra and 
Baranwal 2016). 
 
Hyperacute kidney rejection takes place immediately after the kidney 
transplantation as a consequence of high levels of preformed complement-
activating DSA. This is very rare today, but may occur if HLA immunisation has 
been missed in pre-transplant crossmatch and antibody screening processes. In 
hyperacute rejection, binding of DSA to the vascular endothelium of the transplant 
activates the complement system. This leads to a massive inflammatory response 
and vascular thrombosis (Becker, Morath, Suesal 2016)  




Acute rejection may occur anytime within the first months of the transplantation 
procedure. A T cell-mediated response against foreign HLA is the key factor in 
acute cellular rejection, with infiltrates of CD4+ and CD8+ T cells found in the 
renal interstitium, tubuli and blood vessels. In acute antibody-mediated rejection 
(AMR), donor-specific HLA antibodies attach especially to peritubular capillaries 
and induce damage in the endothelium (Chalasani et al. 2004). 
 
Chronic rejection develops after the acute rejection episodes have subsided. 
Chronic rejections are both antibody- and T cell-mediated (da Silva et al. 2017). As 
the most common type of rejection, chronic rejection is the reason for the majority 
of transplant failures seen today (Moreau et al. 2013).It develops in transplants 
that are exposed to recurring or continuous cellular and humoral responses 
resulting from indirect recognition of alloantigens (Joosten et al. 2005). 
Mononuclear infiltrates with a high number of plasma cells are present. 
Inflammatory events and insufficient immunosuppression can lead to the 
formation of de novo DSA, resulting in long-term damage to the transplant 
(Becker, Morath, Suesal 2016)  
 
Another way to classify rejections is to use the response to steroid administration 
(methylprednisolone) as a criterion. Overall, 60-70% of acute rejections respond to 
steroid treatment and are therefore classified as acute reversible rejections (ARR), 
with the rest of the rejections regarded as steroid-resistant rejections (SRR) (Bock 
2001). Rejections responsive to steroid treatment usually have a cellular origin, 
while rejections without response are more likely of humoral background (Rekers 
et al. 2016). 
 
 
5.3 Histocompatibility and transplant outcome 
 
 
5.3.1 Effect of mismatches 
 
Good matching provides several benefits in kidney transplantation, such as longer 
graft survival, better graft function, and a lower risk for infection and malignancy 
due to reduced level of immunosuppression (Opelz and Dohler 2013). However, 
well-matched transplants are not available for all patients within a reasonable 
waiting time, due to the rarity of some tissue types. Therefore, transplants with 
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differing degrees of HLA mismatching are transplanted consistently. According to 
the early findings of Collaborative Transplant Study in 1985, transplantations 
with no mismatch in HLA-B and –DR show a 20% higher success rate than 
mismatched transplants (Opelz 1985). This difference is still seen in the modern 






Figure 4. Graft survival according to mismatches in HLA-A, -B, -DR. Reproduced with 
permission from the publisher (Collaborative transplant study 2017). 
 
HLA mismatches sustain the risk of sensitisation when the graft is lost. For 
patients waiting for a retransplant, prior mismatches can decrease the chance of 
finding a suitable organ and thus increase the waiting time. 
 
As mismatches carry a risk for complications they also have an effect on the 
medical costs. In the U.S. patients receiving zero mismatch transplants, the 
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average three year medical costs are $60,436, while in patients with a full 
mismatch the transplant costs rise to $80,807 (Schnitzler et al. 1999). 
 
 
5.3.2 Effect of preformed antibodies 
 
Immunisation against HLA antigens lowers the likelihood of receiving a 
transplant as patients with preformed antibodies face a risk of a positive 
crossmatch result preventing transplantation. Since the sensitive solid phase 
assays, like bead array, were implemented in routine antibody screening, there 
has been debate over the relevancy of identified DSA in crossmatch-negative 
situations. There are conflicting reports on the importance of such antibodies 
(Amico et al. 2011; Aubert et al. 2009; Caro-Oleas et al. 2012a; Lefaucheur et al. 
2010). It has become clear that preformed DSA have an effect on the population 
level but the prediction of the clinical course for an individual patient is not that 
simple. 
 
In a study by Riethmuller et al., immunised patients with negative T cell CDCXM 
were transplanted. The 1 year cumulative incidence of AMR was lower in the 
negative VXM than in the positive VXM group (6% vs. 35%, respectively). No 
difference was seen in T cell-mediated rejections (41% vs. 40%, respectively) 
(Riethmuller et al. 2010). It has also been reported that both class I and class II 
DSA increase the risk for graft loss. In patients with class I DSA alone, the relative 
risk (RR) of graft loss was 5.174 (95% CI 2.416–11.079), whereas in patients with 
class II DSA alone RR was 2.576 (95% CI 1.236–5.368) (Caro-Oleas et al. 2012a). 
The MFI value of the detected DSA has a great impact as shown by Lefaucheur et 
al. The prevalence of AMR rises to 0.9%, 18.7%, 36.4%, 51.3% as the MFI of highest 
DSA increases <465, 466-3000, 3001-6000, >6000 MFI, respectively. Similarly, the 
eight year graft survival decreases to 82.5%, 78.4% 60.6% with the rising DSA MFI 
values of <465, 466-3000, >3000 MFI, respectively (Lefaucheur et al. 2010). 
 
 
5.3.3 Effect of de novo DSA  
 
HLA mismatches between the graft and recipient predisposes the patient to 
produce antibodies against the graft. HLA-DR mismatches in particular are of 
importance as due to the strong linkage equilibrium they are often combined with 
DQ mismatches. In addition, HLA class II antibodies have a stronger impact on 
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AMR and graft loss (Willicombe et al. 2011). In a study of 505 patients without 
preformed DSA, 18% developed de novo DSA. DSA against antigens: HLA-A, HLA-
B, HLA-DR, and HLA-DQ associated with AMR and transplant glomerulopathy, 
while HLA-Cw associated only with transplant glomerulopathy. HLA-DQ DSA 
associated with an inferior 40-month allograft survival than non-DQ DSA (76% vs. 
95%) (Willicombe et al. 2012). It must be noted that antibody formation itself is 
not a risk factor if the antibodies are not directed against antigens present on the 
graft. No significant differences in rejection episodes have been observed between 
non-immunised patients and patients with third-party antibodies (Caro-Oleas et 
al. 2012b). 
 
In a study by Everly et al., patients tested post-transplant with single antigen 
beads for DSA IgG, IgG3 and IgM showed additive effect between immunoglobulin 
classes and subtypes. Almost all (95%) of the patients that developed alloimmune 
response presented IgM DSA and half (47%) had IgG DSA. IgM DSA alone did not 
increase the risk for graft loss. However, patients showing IgG isotype switch to 
IgG3 with the persistent IgM (19%) had the highest risk (47%, median 72 month 
follow-up) for graft loss (Everly et al. 2014). 
 
 
5.3.4 Non-immunological factors 
 
There are known donor-related factors involved in transplant outcome, such as 
donor age and cause of brain death. The use of donors with expanded criteria has 
highlighted the importance of donor factors to graft survival. These criteria include 
age either above 60 years or between 50 and 59 years combined with two of the 
following additional characteristic: donor history of cerebrovascular accident, 
hypertension, and a serum creatinine level higher than 1.5 mg/dL (132.6 μmol/L) 
(Johnston et al. 2004). A three year graft survival of 75% was reported for 
expanded criteria donors as compared to 84% for standard criteria donors (Ferrer 
et al. 2009). The recipient and transplant related factors predisposing to 
unfavorable outcome are hepatitis C virus-positivity, high weight, diabetes, 
hypertension, and long waiting time (Caro-Oleas et al. 2013; Khalkhali et al. 2010). 
A study by Gibling et al. shows that cold ischemia time (CIT) has a clear effect on 
graft survival when the first and second kidneys of the donor are compared (Giblin 
et al. 2005). With a mean CIT of 19.9 h for the first kidney and 25.7 h for the second 
kidney, a significant difference was observed in the graft survival rates. Graft 
survival at 1 year was better for the first kidney than for the second one (88.5% vs. 
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84.7%), and the difference persisted at 10 years (55.2% vs. 40%, respectively). 
Altough CIT is a non-immunological factor, a prolonged CIT may elevate humoral 
immunogenicity of the transplant, and promote higher production of HLA class I 
antibodies (Bryan et al. 2001).  
 
 
5.4 Other complications and their relation to immunisation 
 
 
5.4.1 Delayed graft function 
 
In a study by Humar et. al., an elevated PRA of >75% resulted in an elevated risk 
for DGF, (RR 3.4, p= 0.0001) (Humar et al. 2002). Other reported recipient-related 
risk factors for DGF according to multivariate analysis are male gender, BMI>30 
kg/m2, primary cause of ESRD (diabetes), and longer maintenance dialysis. 
Transplant-related factors include HLA mismatches, donor-recipient size-
mismatch, CIT, and low transplant center volume (Doshi et al. 2011).  
 
 
5.4.2 Impaired glomerular filtration 
 
The data on the relation between DSA and GFR is limited. It is known that chronic 
antibody-mediated rejection is caused by DSA and eventually leads to increased 
proteinuria and decreased GFR. Adult patients with DSA have been shown to have 
significantly higher proteinuria levels, and proteinuria seems to be an important 
factor in determining rapid GFR decline (DeVos et al. 2012; Immenschuh et al. 
2015). The direct association between DSA and GFR is somewhat inconclusive. In 
a study by Rusai et al., no association between DSA status and poor GFR was found 
(Rusai et al. 2016). Conflicting results were reported by Chaudhuri et al., 
describing decline of graft function at the presence of DSA (Chaudhuri et al. 2013). 
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5.5 Laboratory techniques measuring immunisation 
 
 
5.5.1 Complement-mediated lymphocytotoxicity test (CDCXM) 
 
This landmark technique was introduced and published in 1964 by Terasaki and 
McClelland in the first histocompatibility workshop (Terasaki and McClelland 
1964). Until then, leukoagglutination had been the most commonly used test to 
identify HLA antigens. This new method, which used only 0.1% reagents compared 
to agglutination test, made it possible to perform the groundwork for identifying 
HLA antigens in HLA workshops (Terasaki 2012). The clinical relevance of this 
test as a measure of immunisation was demonstrated by Patel and Terasaki in a 
study where only eight of 195 (4%) crossmatch-negative kidneys failed, whereas 24 
out of 30 (80%) crossmatch-positive kidneys were lost immediately (Patel and 
Terasaki 1969). Ever since, this test has been used to detect preformed antibodies 
against the graft. In addition to HLA typing, this technique can be used to screen 
and identify pre-formed antibodies or for CDCXM (Fig. 5).  
 
When this test is used for antibody screening, a panel of cells with known HLA 
types is incubated with the serum of interest in the presence of rabbit complement. 
The presence of complement-binding antibodies launches a cascade where a 
membrane attack complex of complement is formed on the target cell surface. As 
a result, channels to the cell surface are formed, allowing staining with otherwise 
non-permeable stains. The readout of the test is the percentage of permeable (dead) 
cells of the total cell population on the scale of 1-8, with the higher scores 
representing a stronger reaction. The proportion of different cells in the panel that 
are subject to killing by the serum antibodies are represented as the percentage of 
PRA. This PRA percentage is used as a measure of the immunisation level. 
Patients with a high PRA are therefore at a higher risk of having antibodies 
against the potential donor.  
 
In the crossmatch, the recipient serum is tested only against the potential organ 
donor. This test detects all antibodies capable of cytotoxicity in the presence of 
complement, being therefore either IgG or IgM. A variant of the test excludes IgM 
antibodies with the use of reducing agent dithiothreitol (DTT). The DTT treatment 
clears disulfide bonds of the IgM molecule tertiary structure, while leaving other 
immunoglobulin classes unaffected (Taylor et al. 1989). The biggest impediment of 
the CDCXM method is the need for viable cells. CDCXM still holds its place as, in 
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this test, the donor antigens are presented in a native form on target cells close to 





Figure 5. CDCXM. 1. Donor cells are incubated with the recipient serum. 2. Antibodies 
identifying donor antigens bind to the lymphocytes. 3. with addition of 
complement cells with complement fixing recipient antibodies lyse. 4. Lysed cells 
are identified with viability staining. 
 
 
5.5.2 Flow Cytometry (FCXM) 
 
Flow cytometric crossmatch was introduced to kidney transplantation protocols in 
1983 (Scornik et al. 1994). This method is considered to be more sensitive, 
quantitative, and objective than CDCXM. In this method, donor lymphocytes are 
incubated with the recipient serum. Recipient antibodies bound to the donor cells 
are identified with a secondary fluorochrome-conjugated antibody against human 
IgG. The use of different fluorochrome-labelled secondary antibodies being easy 
makes it possible to detect different immunoglobulins, such as IgM and different 
IgG subtypes. The cell type of interest can be detected with another set of 
fluorochrome-labelled antibodies, for example T cells with anti-CD3 antibodies and 
B cells with anti-CD19 antibodies. The labelled cells are analyzed with a flow 
cytometer and the results are compared to a negative control (a serum pool from 
non-immunised individuals). Whenever fluorescence against an immuniglogulin is 
Review of the literature
28 
 
detected at at a level that exceeds the threshold for a positive result, the test is 
considered positive (Fig. 6). Similarly to CDCXM, FCXM is not specific to HLA 
antibodies and false positive results occur due to non-HLA antibodies (Kerman et 
al. 1999). As a secondary antibody directed against human IgG is generally used, 
this method detects also non-complement activating antibodies. When B cells are 
used as a target, false positivity is caused by the formation of irrelevant antigen-
antibody complexes through binding of Fc-fragments to the Fc-receptors 
(Altermann et al. 2006; Delgado and Eckels 2008). Eng et al and Le Bas-Bernardet 
et al have reported that at least as many as two thirds of positive B cell 
crossmatches were false positives as no donor-specific HLA antibodies were 
present in the tested sera (Eng et al. 2009; Le Bas-Bernardet et al. 2003). This 
suggests that B cell crossmatch should always be interpreted in combination with 





Figure 6. FCXM. 1. Donor cells are isolated. 2. Recipient serum is added. 3. Antibodies 
identifying donor antigens bind to the lymphocytes. 4. Target cells are identified 
with labelled antibody. 5. Binding of recipient antibodies to the donor cells is 
determined with labelled secondary antibodies. 6. Cells and the binding of 
recipient antibodies are analysed with flow cytometer. 7. Crossmatch result 
presented as a histogram.  
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5.5.3 Bead array 
 
In solid phase assays, solubilized HLA molecules are bound to a surface e.g. 
microtiter plate (enzyme-linked immunosorbent assay) or polystyrene beads (bead 
array) (Hwang et al. 2012; Lachmann et al. 2013). Bead array refers to a single 
commercial platform known as “Luminex” and it is currently the most widely used 
solid phase assay. The Luminex platform utilizes a technology where polystyrene 
beads are filled with two fluorescent dyes in different proportions creating 100 
colour combinations. These staining variants can be detected through the emitted 
fluorescent pattern excited by the red laser of the Luminex analyzer. The binding 
of antibodies to the HLA molecules on the beads is determined with a secondary 
antibody conjugated with R-phycoerythrin (PE). The emission following excitation 
with green laser is directly measured as the fluorescent intensity (Lachmann et al. 
2013) (Fig. 7).  
 
 
5.5.3.1 Antibody detection 
The antibody detection protocol with Luminex consists of two stages: screening and 
identification. The screening kit contains a mixture of beads coated with purified 
HLA antigens pooled from multiple individuals. The identification is performed 
with single-antigen beads, where the antigens are purified from recombinant cell 
lines, one bead carrying only a single antigen. 
 
The threshold for a positive result in a single-antigen analysis has been under 
debate as long as bead array techonology has been available (Liu et al. 2012; Piazza 
et al. 2014; Riethmuller et al. 2010). The assay was originally developed for 
qualitative use only, but as it provides fluorescent intensity against each antigen, 
the fluorescent value is used as a surrogate to address antibody strength in many 
studies (Chung et al. 2014; Ellis et al. 2012; Wu et al. 2013). Different values for 
clinically relevant thresholds for different conditions have been described as 
varying from 500 to 5000 MFI, while the generally used threshold for reporting a 
positive result is 1000 MFI. Separate clinical endpoints might be differentially 
affected by various quantities of antibodies (AMR, DGF, Graft loss) and the 
clinically relevant antibody level may vary depending on the endpoint measured 
(Bradley et al. 2011; Lefaucheur et al. 2010). 
 





Figure 7. Antibody detection by bead array. 1. Polystyrene beads covered with HLA 
antigens are used. 2. Patient serum is incubated with the beads. 3. HLA 
antibodies present at the serum will bind to the beads. 4. HLA antibodies are 
identified with labelled secondary antibody against human IgG. 5. The bead 
carrying the HLA antigen is identified by the bead analyzer by one laser and the 
amount of IgG antibodies bound to the bead is identified by another laser. 6. The 
result is visualised by the analysis software. 
 
 
There are some technical limitations to the assay. First, the amount of antigen on 
each bead is not standardized, resulting in differences in the amounts of various 
antigens on the bead surface. An antigen that is saturated on a bead will produce 
higher fluorescence values than antigens present at a lower density. Second, the 
densities of antigens on the beads are not in proportion to the densities found on 
the cell surface (Lachmann et al. 2013). HLA-Cw has markedly lower expression 
than other class I antigens and yet its density on the beads is similar to that of 
other class I antigens (Apps et al. 2015). Thus, antibodies against HLA-Cw are 
over-detected. Third, it has been reported that the conformation of HLA molecules 
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on the beads is sometimes affected by the manufacturing process leading to 
abnormal positivity (El-Awar et al. 2009). In addition, as the number of beads in 
the analysis is limited, the extensive variation seen in the HLA region cannot be 
represented comprehensively and therefore some antibodies may not be identified. 
 
The sample itself may cause limitations. It has been reported that a high level of 
HLA-IgM antibodies may block the binding of IgG antibodies, resulting in false 
negative results (Kosmoliaptsis et al. 2009). Also, complement components can act 
as blocking agents for the secondary antibody used in the assay (Schnaidt et al. 
2011). This phenomenon is now widely recognized and measures have been taken 
to eliminate the problem (Kosmoliaptsis et al. 2010; Zachary et al. 2009a). 
Treatment of sera with ethylenediaminetetraacetic acid (EDTA) has proven to be 
the most effective solution for false negative results and is now widely used in HLA 
laboratories worldwide (Schnaidt et al. 2011). 
 
The main advantage brought by the bead array is the possibility to modify the 
standard assay with alternative secondary antibodies to enable the detection of 
different immunoglobulin classes or IgG subtypes. With additional steps it is also 
possible to detect capacity forcomplement binding (Loupy et al. 2013). 
 
 
5.5.3.2 Luminex crossmatch (LXM) 
The most innovative variant of the bead array is the Luminex crossmatch. In this 
assay, donor cells are lysed and HLA antigens are captured on the beads by HLA 
antibodies to produce beads with all HLA antigens of the individual donor. 
Therefore LXM enables an HLA-specific crossmatch. One of the advantages of 
LXM is that the preformed antibodies are routinely identified with the same 
technique and therefore it should carry a high predictive value. Indeed, it has been 
shown that there is a good correlation between the screening and crossmatching 
for HLA- A, -B, -C, DRB1 (Caro-Oleas et al. 2010). However, some findings suggest 
that the beads may not capture HLA-DQ and HLA-DP antigens as efficiently as 
other antigens (Billen et al. 2008; Caro-Oleas et al. 2010).  
 
 
5.5.4 Calculated PRA (CPRA) 
 
Calculated PRA, based on identified antibodies, has replaced the traditional cell 
panels in many laboratories. CPRA is calculated as the percentage of donors 
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identified in the population by the antibodies present in the potential recipient´s 
serum. This gives a much better estimate than the traditional PRA assessed with 
cell panels. These cell panels were not representative of the donor population as 
rare antigens were over-represented at the expense of common antigens. On the 
other hand, the Luminex technology used in CPRA shows a much higher 
sensitivity than the traditional complement-mediated lymphocytotoxicity test 
(CDC) method. As antibodies used in the PRA calculations are detected with a 
higher sensitivity than before, the CPRA of the patients on the waitlist has 
increased (Baxter-Lowe et al. 2016). 
 
 
5.5.5 Virtual crossmatch (VXM) 
 
A virtual crossmatch is performed by comparing the antibodies identified in the 
recipient serum with the HLA antigens of a particular donor. The presence of DSA 
indicates a positive crossmatch. The standard procedure for VXM is to identify 
antibodies with a sensitive method (Luminex) and HLA type the donor for every 
loci against which antibodies are present in the recipient serum (EFI Standards 
2017). However, the term VXM is used in two very different scenarios. Usually 
VXM is performed together with a prospective CDCXM or FCXM, giving additional 
risk stratification for a negative “physical” crossmatch. In Finland, this strategy is 
used for living donor transplants. VXM is also used on its own, omitting a 
prospective “physical” crossmatch before entering the operating theatre. A 
common practice is to combine VXM and prospective crossmatch strategies. 
Patients with a negative VXM will be transplanted without a prospective 
crossmatch, while patients with a positive VXM will be transplanted only if the 
prospective crossmatch is negative. With this approach, a lower 1 year cumulative 
incidence of clinical/subclinical AMR rate was observed in the negative VXM group 
compared with the positive VXM group (8% vs. 42%, respectively), along with 
superior death censored allograft survival at 2 years (98% vs. 91%, respectively) 
(Amico et al. 2011).  
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6 AIMS OF THE STUDY 
 
 
The goal of this thesis was to study the prevalence of HLA antibodies and evaluate 
the relevance of DSA for the graft outcome. Also, the performance of different 
methods used for evaluating the immunisation status of kidney transplant 
patients were compared. 
 
The specific aims of the study were: 
1. To assess the usefulness of population-based virtual PRA in comparison with 
the traditional panel in addressing immunisation status. 
 
2. To study incidence of HLA antibodies in pediatric kidney transplant patients 
and their significance on graft function. 
 
3. To analyze prevalence of preformed HLA antibodies and their impact on early 
kidney graft function. 
 
4. To compare the predictive value of antibody screening results with different 
crossmatch methods and develop practices in histocompatibility testing. 
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7 MATERIALS AND METHODS 
 
 
7.1 Study subjects 
  
Study I. The HLA data from the Finnish Bone Marrow Donor Registry and Finnish 
Cord Blood Bank (19,807 and 2,699) were included for HLA allele frequency 
calculations. Haplotypes were determined for 504 individuals genotyped at a high-
resolution level. For virtual PRA calculations, 30 serum samples from HLA 
antibody positive patients were used. 
 
Study II. The work included 288 latest serum samples from 235 patients waiting 
for a kidney transplant in Finland. The patient sera were crossmatched against 
splenocytes from 40 consecutive deceased donor. 
 
Study III. Altogether 123 pediatric kidney transplant patients transplanted at 
Children´s Hospital, Helsinki University Hospital, between 1989 and 2004, were 
included. Patients were selected if serum samples were available for HLA antibody 
screening and identification, and sufficient follow-up data were available. 
 
Study IV. The study group included a total of 771 adult (≥16 years) patients who 
had received a deceased donor transplant at Helsinki University Hospital between 
2000 and 2004. Only patients without surgical complications or thrombosis related 
to transplantectomy were included. 
 
 
7.2 HLA typing (I, II, III, IV) 
 
HLA typing was performed in the Histocompatibility Testing Laboratory of the 
Finnish Red Cross Blood Service. Results were reported according to the current 
World Health Organization nomenclature. Deceased donors were initially typed 
with the CDC (Biotest Rockaway, NJ, USA) and polymerase chain reaction with 
sequence-specific primers (One Lambda Inc., Canoga Park, CA, USA). Further 
supplementary typing was performed with polymerase chain reaction with 
sequence-specific oligonucleotide probes (SSO) (One Lambda) or with Sanger 
sequencing (SBT) (Atria Genetics, South San Francisco, CA, USA) in situations 
where donor-specificity of an antibody was unclear. The typing methods for the 




Bank vary depending on the time of initial typing. At least CDC, SSO and SBT 
were used for typing registry donor candidates. 
 
 
7.3 HLA antibody screening and identification (I, II, III, IV) 
 
HLA antibodies were screened with commercial bead array kits (LABScreen® 
Mixed, One Lambda). Antibodies detected in the screening were identified with 
LABScreen® single antigen kits (One Lambda), with a cut-off value of the baseline 
normalized value of 500/1000 MFI. Antibodies were determined against all 
classical HLA class I (HLA-A, -B and -Cw) and class II (HLA-DR, -DQ and -DP 
antigens. In study II, also LABScreen® PRA kits were used. Antibody specificities 
were assigned with the HLA Visual™ or HLA Fusion™ software.  
 
 
7.4 Complement-mediated lymphocytotoxicity crossmatch (II, III, IV) 
 
CDCXM was performed on-call with donor splenocytes (Amos et al. 1969). Parallel 
crossmatches with different volumes of recipient serum (0.1 μl, 1 μl, 5 μl) were 
performed in duplicate. International workshop scoring was used to score the 
percentage of cell death with the modification that any cell death above 
background considered as positive: score 1: <1%; 2: 1-20%; 4: 21-50%; 6: 51-80%; 8: 
81-100%. No DTT was used to neutralize IgM antibodies. 
 
 
7.5 Flow cytometric crossmatch (II) 
 
Retrospective T cell IgG, T cell IgM, and B cell IgG FCXM were performed with 
frozen deceased donor splenocytes (Matinlauri et al. 2004). In each test, 500 000 
splenocytes with 50 μl of serum were used. T and B cell populations were identified 
with PE-anti-CD3 and PE-anti-CD19 (BD Biosciences, San Jose, CA). The binding 
of IgG antibodies was detected with FITC-conjugated F(ab)2 anti-human IgG 
(Jackson ImmunoResearch, West Grove, PA). Crossmatches were analyzed using 
FACScan instrument (BD Biosciences). A cut-off of 40 channel shifts for T cells and 






7.6 Luminex crossmatch (II) 
 
LXM was performed according to the manufacturer’s protocol, with the exception 
of using frozen splenocytes for the lysate preparation. For individual tests, a lysate 
of 2.2 x106 splenocytes was used. Donor antigens of the lysate were captured on 
the bead array beads with anti HLA class I or class II antibodies. The serum of 
interest was incubated with the beads coated with donor class I or class II HLA 
antigens. Binding of HLA antibodies to captured donor antigens was detected with 
PE conjugated anti-human IgG. Samples were run on Luminex (LabScan 200) and 
analysed with LifeMatch software (Tepnel, Lifecodes). A user-specific threshold for 
a positive result with MFI values above 1000 against all three negative control 
values was used. 
 
 
7.7 Virtual crossmatch (II, IV) 
 
For VXM, DSA were assigned by comparing detected antibodies to the donor’s 
HLA. When DSA were identified, VXM was considered positive. The strength of 
VXM was described as cumulative DSA. The sum of all individual DSA above 1000 
MFI was reported as the cumulative DSA. 
 
 
7.8 Calculated (virtual) PRA (I) 
 
For calculated PRA, the HLA fusion™ software with imported population data was 
used for the calculations of the Finnish population and the EuroTransplant 




7.9 Clinical data (III, IV) 
 
Clinical data were collected retrospectively from hospital records. This data 
included: kidney disease leading to RTx, recipient’s age, and gender, BMI (Study 
IV), age of donor (Study III), HLA of recipient and donor, date of transplantation, 
transplant number, rejection episodes, CIT, DGF, kidney graft function with GFR, 
graft outcome, cytomegalovirus status (Study III), and allograft biopsy results at 




7.10 Clinical endpoints 
 
 
7.10.1 Delayed graft function (IV) 
 
DGF was defined as fulfilment of one of the following criteria: serum creatinine 
>500 μmol/L throughout the first perioperative week, more than one dialysis 
session during the first week after transplantation, or oliguria (<1 L/day) two days 
after transplantation (Halloran et al. 1988). Conventional DGF was defined as a 
need of dialysis on the first perioperative week and slow graft function as an 
impaired creatinine clearance without need for dialysis (Humar et al. 1997).  
 
 
7.10.2 Glomerular filtration rate (III) 
 
GFR was measured as the total plasma clearance of Chromium-51 labelled 
ethylenediaminetetraacetic acid (Jodal and Brochner-Mortensen 2009). GFR 
values were corrected according to modified Brochner-Mortensen equation. GFR 
was measured at 3 and 6 months after RTx, and then annually with an average of 
9 measurements per patient. 
 
 
7.11 Bioinformatics and statistical analysis 
 
Categorical variables were analysed with the Fisher’s exact test. Binary logistic 
regression analysis or Mann–Whitney U-test was used to compare continuous 
variables. Sensitivity and specificity were assessed with the ROC analysis. The 
accuracy of the test was classified as the AUC with 0.9-1: excellent; 0.8-0.9: good; 
0.7-0.8: fair; 0.6-.07: poor; 0.5-.06: fail. Results with a P value of ≤0.05 were 
considered statistically significant. All presented P values are uncorrected for 
possible multiple testing. Analyses were performed with the SPSS statistics 
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8.1 HLA haplotype frequencies and calculated PRA (I) 
 
HLA allele and antigen frequencies of the Finnish population were studied. Also, 
the most common Finnish high-resolution haplotypes for five HLA loci were 
determined. Calculated population specific PRA was determined by correlating 
identified antibodies to the Finnish HLA population data.  
 
 
8.1.1 HLA haplotypes 
 
The genotypes of the Finnish patients waiting for stem cell transplantation were 
used for HLA haplotype analysis. A total of 372 different haplotypes were 
identified from 504 individuals. The most common HLA haplotypes and their 
frequencies are presented in Table 2. The most common Finnish haplotype: 
A*03:01-B*35:01-C*04:01-DRB1*01:01-DQB1*05:01 dominated, being much more 
common than any other haplotype. The frequency of the second most common 
haplotype A*01:01-B*08:01-C*07:01-DRB1*03:01-DQB1*02:01 was 37% lower. 
 
 
8.1.2 Calculated PRA 
 
PRA values were measured with a panel (LabScreen PRA) and by virtual 
calculation with either the Finnish or Eurotransplant population data 
(Eurotransplant Reference Laboratory 2018) as the point of comparison. PRA 
values obtained via the population-based calculation were clearly higher than 
values obtained with the panel, resulting in twice (15/30 vs. 7/30) the proportion of 
highly immunised patients (PRA I or II ≥80 %). The calculated PRA values for 
Finnish patients were determined in accordance with both the Finnish and 
Eurotranplant haplotype frequencies. The differencies seen between these values 





Table 2. The 40 most common Finnish HLA haplotypes and their frequencies 
(2n=1008).  
A* B* C* DRB1* DQB1* n Frequency 
03:01 35:01 04:01 01:01 05:01 72 0.0714 
01:01 08:01 07:01 03:01 02:01 46 0.0456 
03:01 07:02 07:02 15:01 06:02 23 0.0228 
02:01 13:02 06:02 07:01 02:02 22 0.0218 
02:01 07:02 07:02 15:01 06:02 21 0.0208 
02:01 15:01 03:03 13:01 06:03 21 0.0208 
02:01 15:01 03:04 04:01 03:02 20 0.0198 
02:01 27:05 02:02 08:01 04:02 20 0.0198 
03:01 07:02 07:02 13:01 06:03 13 0.0129 
02:01 15:01 04:01 08:01 04:02 12 0.0119 
68:01 08:01 07:01 03:01 02:01 11 0.0109 
24:02 40:01 03:04 13:02 06:04 11 0.0109 
03:01 15:01 03:03 08:01 04:02 11 0.0109 
02:01 40:02 02:02 04:05 03:01 10 0.0099 
24:02 07:02 07:02 15:01 06:02 10 0.0099 
24:02 39:01 07:02 04:04 03:02 9 0.0089 
03:01 15:01 03:04 04:01 03:02 9 0.0089 
02:01 27:05 01:02 04:08 03:01 9 0.0089 
03:01 18:01 07:01 04:04 03:02 8 0.0079 
02:01 56:01 01:02 04:01 03:02 8 0.0079 
02:01 44:02 05:01 12:01 03:01 7 0.0069 
02:01 27:05 02:02 01:01 05:01 7 0.0069 
02:01 40:01 03:04 08:01 04:02 7 0.0069 
02:01 27:05 02:02 04:04 03:02 6 0.0060 
02:01 44:02 05:01 04:01 03:01 6 0.0060 
31:01 18:01 07:01 15:01 06:02 6 0.0060 
25:01 18:01 12:03 15:01 06:02 6 0.0060 
02:01 56:01 01:02 04:01 05:03 6 0.0060 
02:01 08:01 07:01 03:01 02:01 6 0.0060 
02:01 40:01 03:04 13:02 06:04 6 0.0060 
24:02 07:02 07:02 13:01 06:03 6 0.0060 
25:01 18:01 12:03 01:01 05:01 6 0.0060 
02:01 35:01 04:01 01:01 05:01 6 0.0060 
24:02 39:01 07:02 08:01 04:02 6 0.0060 
02:01 44:27 07:04 16:01 05:02 5 0.0050 
03:01 35:01 04:01 04:01 03:02 5 0.0050 
32:01 44:02 05:01 04:01 03:02 5 0.0050 
03:01 35:01 04:01 15:01 06:02 5 0.0050 
02:01 51:01 15:02 09:01 03:03 5 0.0050 
23:01 44:03 04:01 07:01 02:02 5 0.0050 
            Total 0.4790 




Table 3. Calculated PRA percentages for immunised patients in Finnish and 













1 B76,B45,B44,B82,A1 16 28 48 -20
1
DQ7,DQ2,DR17,DR8,DQ4,DQ8,DQ9,DR13,DR14,DR16,DR11,DR18,DR7,DR12
,DR15,DR52,DQ6,DR103,DR4,DR51 97 95 98 -3
2 DR51,DR103,DR1,DR16,DR10,DR15,DQ4,DR9,DQ2,DQ5,DQ6,DR8,DR11,DR1
7,DR13
77 97 96 1
3
Cw6,Cw18,Cw15,B45,B44,Cw2,B76,B82,Cw5,Cw8,Cw17,B37,B47,Cw4,B13,B27,
B51,B49,B53,B41,B61 62 67 73 -6
3 DR53,DQ8,DR4,DQ9,DQ7,DQ4,DR51,DR15,DQ2,DR16,DR9,DR7,DR10,DR8 86 89 91 -2
4 A3,A34 11 42 29 13
5 DR9,DR51,DR103,DR10,DR1,DQ5,DQ6,DR7,DR15 49 83 77 6
6 B45,B76,B44,B59,B51,Cw4,B27,B63 15 52 55 -3
7 A32,A25,A66,B51,A26,B52,B59,B49,B53,B63,A23,A24 18 40 48 -8
7
DR8,DR12,DQ2,DQ8,DQ4,DQ7,DR7,DQ9,DR52,DR17,DR9,DR14,DR11,DR13,
DR18,DR4 86 90 93 -3
8 A25,A26,A66,B62,B76,A34,A43,B77,A11,B63,B75,B57,B13,A31,B72,A29,A30,A33,
A74,B50,A32,B58
49 47 59 -12
8 DQ5,DQ2,DR10,DR1,DQ6 40 84 81 3
9
A25,A26,Cw18,Cw17,Cw6,Cw5,Cw2,A69,Cw8,A34,Cw15,A33,A66,A24,A68,Cw4,
A2,B63,B54,B39 62 90 90 0
9 DR1,DR103,DR9,DR51,DR16,DR10,DR15,DR53,DR8,DR11 49 94 88 6
10 DR4 14 26 26 0
11 A2,B27,B37,B47,A69,A68,B44,B51,A23,A24,B53,B59 55 83 79 4
11
DR1,DR4,DP9,DR103,DR8,DP17,DP18,DR13,DP2,DR10,DP3,DP4,DP14,DR11,
DP28,DR51 49 99 88 11
12 A33,A31 4 8 8 0
13 A26,A25,A66,A43,A34,A33,A11,A68,A29,A69 47 31 31 0
13 DR15,DR51,DR13 34 52 48 4
14 A3,A34,A66,A26,A11,A33,A29,A30,A25,A32,A31,A1,A36 16 79 79 0
14 DR8,DR16,DR11,DR103,DQ8,DR15,DR12,DR51,DQ4,DR13,DQ7,DQ6,DR7, 
DQ5,DQ9,DR1,DR4,DR10,DR9,DR53
91 99 98 1
15 DR103,DR16,DR14,DR53,DR4,DR7,DR15,DR1,DR9,DR10,DR51,DR8,DR11 89 95 92 3
16 A2,A69,B82,A68,Cw5,B76,A32 11 66 63 3
17 A69,A24,B57,A68,B58,A2,B45,B44,A23,B82,B76,B13,B41 62 81 78 3
18 DR51,DR9,DQ6,DR1,DR103,DR10,DR15,DR53 26 91 85 6
18
A24,A23,B53,B38,B63,B57,A25,B77,A32,B59,B76,B51,B58,A80,B62,B52,B49,B75,
B13,A1,B46 62 64 75 -11
19 Cw7,B73,Cw18,Cw6,B8,Cw4,A25 24 87 77 10
20 DR8,DR12 14 26 10 16
21
B41,B45,B44,B61,B50,B47,B13,B49,B60,B27,B81,B48,B7,B76,B82,B73,Cw12, 
A66,B37 44 72 70 2
22 DR8,DR12,DR13,DR16,DR11,DR7 89 62 68 -6
23 B62,B52,B72,B48,B50,B49,B37,B13,B77,B63,B76,B60,B44 25 49 54 -5





PRA, panel reactive antibody; cPRA, calculated panel reactive antibody; Fi, Finnish 
population; Eu, Eurotransplant population. Modified from publication I Table 5 © 2013 












25 B63,A2,A69,A68 5 61 55 6
26 DR9,DP19,DP20,DR52,DP2,DP28,DR14,DP15,DQ9,DQ6,DR4,DR11,DP5 46 88 92 -4
27 A33,A31,B78,Cw17,B72,B55 4 10 11 -1
27 DR12,DR13,DR11,DR15 20 59 65 -6
28 A32,B51,B59,B53,B44,B27,B13,B38,B49,B77,B37,B47,B52,B63,B57,A26,A66,B58
,A24,A23
55 63 72 -9










8.2 DSA predicting crossmatch outcome (II) 
 
The results of the actual crossmatches, performed with different methods, were 
evaluated against the VXM results. The aim was to define appropriate cut-off 
values for DSA that would predict the crossmatch results generated by different 
crossmatch techniques. This study included routine on-call crossmatches, and the 




8.2.1 HLA antibody status 
 
Of the performed crossmatches, 32% (118/364) were performed with sera from 
sensitised patients while 23% (83/364) of the crossmatches were performed with 
serum containing antibodies against donor HLA. Antibodies were present against 
all HLA loci, but most commonly against HLA-B antigens (28% (101/364)). 
Correspondingly DSA were most frequently directed against donor HLA-B (13% 
(48/364)) (Fig. 8). 
  
 
Figure 8. Prevalence of HLA antibodies and DSA in crossmatches. Modified from 




8.2.2 DSA detected by different crossmatch methods 
 
Eighty-three of the crossmatches were performed with DSA-positive sera. The 
detection rates for DSA in FCXM, LXM and CDCXM were 83%, 71% and 66%, 
respectively. Reverse results were seen in DSA-negative crossmatches where the 
highest rate of false positive tests was seen in CDCXM (20%), followed by LXM 
(11%), and FCXM (10%). The true positive crossmatches correlated well between 
the techniques (Fig. 9A). However, the false positive crossmatches seemed to be 







Figure 9. Crossmatch positivity of individual samples in each technique. (A) Crossmatches 
of DSA positive samples. (B) Crossmatches of DSA negative samples. The sizes 
of the areas are directional only. Modified from publication II Figure 3 © 2018 
Elsevier B.V. All rights reserved. 
 
 
As CDCXM was performed with a mixed T and B cell population, separation for 
class I and II antibodies was not possible. Similarly, FCXM performed with T and 
B cells was not able to separate class I and II antibodies. For samples with only 
class I antibodies, T cell FCXM and B cell FCXM detected the DSA with very 





detection rate was achieved with B cell FCXM than with T cell FCXM (76% and 
41%, respectively). LXM achieved a clear separation between class I and II 
antibodies, with class I LXM detecting 62% of class I and 12% of class II DSA. 
Correspondingly, class II LXM detected 65% of class II DSA and only 5% of class I 
DSA (Table 4). 
 
 
8.2.3 Sensitivity, specificity and accuracy 
 
The diagnostic ability of each crossmatch method was studied by ROC analysis. 
The predictive accuracy for CDCXM was fair (AUC 0.724). LXM and FCXM showed 
good performance, with AUC of 0.805 and 0.861, respectively (Fig. 10). 
 
With a routine cut-off level of 1000 MFI, the best sensitivity for DSA detection was 
reached with FCXM (0.722). While LXM produced almost similar sensitivity 
(0.667), considerably lower sensitivity was obtained with CDCXM (0.495). In terms 
of specificity, less variation was seen between the methods. Again, FCXM 
performed better, offering higher specificity than LXM and CDCXM (0.940, 0.905 
and 0.803, respectively). Similar results were seen with regard to accuracy as 





























































































































































































































































































































































































































































































































Figure 10. ROC curve analysis of DSA in comparison with different crossmatch methods. 
CDCXM, AUC 0.724; FCXM, AUC 0.861; LXM, AUC 0.805. The linear part of 
the curves represents repeated MFI values of 0 (no DSA identified). Modified 
from publication II Figure 2 © 2018 Elsevier B.V. All rights reserved. 
 
 
8.3 DSA and graft function (III) 
 
 
8.3.1 Immunisation status 
 
HLA antibody levels were retrospectively analysed in 123 pediatric kidney 
transplant patients. Of the 294 routinely collected post-transplant serum samples, 




presented antibodies directed against the allograft (Fig. 11). A third of the patients 
(42/123, 34%) had DSA at some time point after transplantation. Class I DSA were 
detected in 10% (12/123) and class II DSA in 19% (23/123) of the patients, while 
both class I and II DSA were detected in 6% (7/123) of the patients. The fraction of 
DSA-positive samples increased over time from 15% at ≤2 years to 20% at 3-5 years 




Figure 11. Percentage of HLA antibodies in pediatric kidney transplant patients at three 
time points after transplantation. A total of 294 serum samples were collected 
and analyzed for HLA antibodies. AB, no HLA antibodies; non DSA, HLA 
antibodies not specific against donor antigens; DSA+, donor specific HLA 







8.3.2 DSA and GFR 
 
A total of 1152 GFR measurements, with an average of 9 measurements per 
patient, were included in this study. There were no differences in measured GFR 
at three years post-RTx or at any time point during the follow-up in four subgroups 





Figure 12. GFR values 3 to 10 years after kidney transplantation according to HLA-
antibody status of the patients and strength of cumulative DSA determined 0-2 
years after transplantation (DSA 500-5000 MFI and DSA > 5000 MFI). No 
statistical difference was observed between patients with no HLA antibodies 
(AB-) and patients with either HLA antibodies not specific against donor 
antigens (nonDSA) or patients with donor-specific HLA antibodies (DSA) at any 
time point (p>0.05). Modified from publication III Table 4 © 2012 Springer. All 
rights reserved. 
 
Surveillance allograft biopsies from kidney transplants were taken simultaneously 
with HLA antibody screening at 1.5 and 3 years after transplantation from 64 and 
75 patients, respectively. Chronic lesions were detected after 1.5 and 3 years in 
31% (20/64) and 47% (35/75) of the patients, respectively. At 3 years after 
transplantation, chronic lesions were seen in 51% (36/71) of the patients without 




At 7 years, there were no differences in the presence of chronic lesions between 
patients without and with DSA (51% (23/45) and 44% (7/16), respectively 
(P=0.7723)). Patients showing both DSA and a chronic histological lesion during 
the first three years after transplantation had lower GFR values (49 
mL/min/1.73m2) than patients without DSA and with normal histological findings 
(64 mL/min/1.73m2). A decrease in GFR during the follow-up was seen with both 
DSA and chronic histological lesions (Fig. 13). However, statistical difference was 
only seen between DSA-positive patients with and without chronic lesions at 3 






Figure 13. Comparison of GFR values at 3 to 10 years post-transplant with HLA antibody 
and allograft biopsy findings taken at time point of 1.5 and 3 years after 
transplantation. GFR at 3 years after transplantation: DSA+, normal vs. DSA+, 
IF/TA, P=0,040. DSA, donor specific HLA antibodies; IF/TA, interstitial 





8.4 Delayed graft function (IV) 
 
Many patients have DSA prior to transplantation when measured with bead array, 
even if the prospective CDC crossmatch gives a negative result. In this study, we 
examined the impact of pretransplant DSA of RTx patients on DGF. 
 
 
8.4.1 Characteristics of recipients according to DGF status 
 
As seen in Table 5, both the recipients and donors were older in the DGF group. 
Patients with early graft function were less immunised than patients with DGF 
and had a significantly lower amount of DSA. Among patients with DGF, the cold 
ischemia time was longer and the rate of previous transplants was higher (Table 
5). 
 
Table 5. Characteristics of recipients with early and delayed graft function 
 
  EF (n=544) DGF (n=227) P-value 
Mean recipient age, yearsr 48 50 0.0348 
Mean donor age, years 44 51 <0.0001 
Male recipients, n (%) 344 (63) 152 (67) 0.3646 
Average HLA mismatch 2.18 2.17 0.8296 
HLA immunised, n (%) 172 (32) 93 (41) 0.0157 
DSA positive, n (%) 54 (10) 49 (22) <0.0001 
Retransplants, n (%) 42 (8) 38 (17) 0.0004 
Cold ischemia time, hoursr 21.53 23.06 <0.0001 
EF, early function; DGF, delayed graft function; DSA, Donor-specific antibody; HLA, 
human leukocyte antigen. Modified from publication IV Table 1 © 2016 Oxford University 
Press on behalf of ERA-EDTA. All rights reserved. 
 
 
8.4.2 Independent predictors for DGF 
 
Several independent predictors were found for DGF in multivariate analysis 
(Table 6). The highest relative risks for DGF were the presence of DSA and 





Table 6. Factors associating with DGF in multivariate logistic regression analysis 
 
Characteristic RR 95% CI P 
Recipient age, years 1.001 0.987-1.016 0.8611 
Recipient BMI, kg/m2 1.047 0.995-1.102 0.0758 
Re-Tx 1.879 1.064-3.319 0.0297 
Rejection ≤ 1 week 0.808 0.177-3.687 0.7830 
Donor age, years 1.037 1.022-1.053 <0.0001 
Donor BMI, kg/m2 1.049 1.004-1.095 0.0331 
CIT, hours 1.068 1.025-1.112 0.0015 
DSA 2.039 1.246-3.335 0.0046 
BMI, body mass index; CIT, cold ischemia time; DGF, delayed graft function; DSA, Donor-
specific antibody; Re-Tx, previous kidney transplant; RR, relative risk. Modified from 
publication IV Table 2 © 2016 Oxford University Press on behalf of ERA-EDTA. All rights 
reserved 
 
There were some differences in the frequency of DGF and presence of DSA (yes/no) 
depending on the primary cause of ESRD. The highest rate of DGF (45%) was 
detected in recipients with unknown etiology of kidney failure, while recipients 
with hypertension/large vessel disease had the lowest DGF rate (19%). DSA were 








Figure 14. Primary cause of ESRD and incidence of DGF and DSA. DGF, delayed graft 
function; DSA, Donor-specific antibody, ESRD, end-stage renal disease. 
 
 
8.4.3 Immunisation status and DGF 
 
One third of the patients (265/771; 34%) had pre-existing HLA antibodies before 
kidney transplantation. Class I antibodies were detected in 225 (29%) patients and 
class II antibodies in 131 (17%). The majority (162/265; 61%) of the immunised 
patients presented non-DSA antibodies. In total, DSA were detected in 103/771 
(13%) of the patients. 
 
The risk of pre-immunisation is largely due to donor-specificity of the antibodies 
as HLA antibodies against third-party antigens had no effect on the DGF rate 
when compared to non-immunized patients (28% vs. 26%, p = 0.6098) (Fig. 15). 
Conversely, patients with DSA had a significantly higher incidence of DGF when 











Figure 15. Comparison of immunisation status with DGF. AB-, no detected HLA 
antibodies, DGF, delayed graft function; DSA, Donor-specific antibody; non-
DSA, antibodies against a third party. Modified from publication IV Figure 1 © 
2016 Oxford University Press on behalf of ERA-EDTA. All rights reserved 
 
The number of antigens detected as DSA had an effect on that DGF rate as 
recipients with a single DSA had a DGF incidence of 43%, whereas patients with 
two or more DSA had DGF rates of 57% and 53%, respectively (P < 0.0001). The 
strength of DSA as measured by cumulative DSA MFI showed a good predictive 
value as well. The incidence of DGF was more than twice as high in patients with 
DSA of 3000–5000 MFI when compared to patients with DSA of 1000-3000 MFI or 
patients without DSA (65%, 31% and 27% respectively; P = 0.0351) (Table 7). 
 
 
8.4.4 DSA and rejections 
 
Of the patients, 17% (129/771) were diagnosed with at least one episode of acute 
rejection during the follow-up. Of the rejections, 15% (19/129) were steroid 
resistant. No association with DSA positivity or the total DSA MFI value was seen 
in ARR. However, steroid-resistant rejections were more common in patients with 
a cumulative DSA MFI of > 5000 than in patients without DSA (14% vs. 2%, P = 




Table 7. The incidence of DGF according to the number of DSA and the cumulative 
MFI value 
    Delayed Graft Function 
DSA status N n (%) P-value 
DSA number    <0.0001 
   no DSA 668 178 27  
   1 DSA 65 28 43 
   2 DSA 21 12 57  
   ≥3 DSA 26 9 53  
Cumulative DSA    <0.0001 
   no DSA 668 178 27  
   1000-3000 MFI 22 10 31  
   3000-5000 MFI 18 11 65  
   >5000 MFI 43 23 53   
DSA, donor-specific antibody; MFI, mean fluorescent intensity. Modified from publication 
IV Figure 1 © 2016 Oxford University Press on behalf of ERA-EDTA. All rights reserved 
 
 
Figure 16. Association of cumulative DSA MFI with rejections. Univariate analysis 
performed with two-tailed Fischer’s exact test. ARR, acute reversible rejection; 







This thesis evaluated the role of HLA antibodies in kidney transplantation from 
two different angles. The first two publications analysed various techniques used 
to measure the immunisation status of patients and the sensitivity and specificity 
of different crossmatch techniques. The last two publications evaluated the 
importance of HLA antibodiesin the transplant outcome. The study endpoints were 
long-term graft function as measured by GFR and early graft function as assessed 
by DGF. These retrospective clinical studies were performed in pediatric and adult 
kidney transplant patients. 
 
 
9.1 The importance of knowing your population 
 
This study provided new information on the distinctive features of HLA antigens 
in the Finnish population. Although the allelic diversity in the Finnish population 
is limited when compared to other European populations, the enrichment of 
certain haplotypes makes the population unique. The most common Finnish 
haplotype: A*03:01-B*35:01-C*04:01-DRB1*01:01-DQB1*05:01 is much more 
frequent in Finland than in the population of European background in the US 
(frequency of 0.0714 and 0.0126, respectively) (Maiers, Gragert, Klitz 2007). The 
most common European haplotype A*01:01-B*08:01-C*07:01-DRB1*03:01-
DQB1*02:01 is particularly common in North West England, where its frequency 
is twice as high as that seen in Finland (0.0950 and 0.0456, respectively) 
(Gonzalez-Galarza et al. 2011). In addition, there are population-specific 
haplotypes, such as the Finnish haplotype A*31:01-B*51:01-C*01:02-DRB1*13:01-
DQB1*03:03, that do not exist at all in the population of European background in 
the USA (Maiers, Gragert, Klitz 2007). There are also some common European 
haplotypes that were not detected in the Finnish population at all, such as 
A*33:01-B*14:02-C*08:02-DRB1*01:02-DQB1*05:01, which is the second most 
common haplotype in the Italian population (Rendine et al. 2012). 
 
The dominance of the most common Finnish haplotype: A*03:01-B*35:01-C*04:01-
DRB1*01:01-DQB1*05:01 is evident, as this haplotype is much more frequent in 
Finland than anywhere else. After the publication of study I, other studies 
describing the unique features of the Finnish population have also been carried 




being HLA homozygous is elevated in Finland. This phenomenon is particularly 
evident for HLA-A for which a homozygosity rate of 11% is seen in the American 
population, while in the Finnish population, this rate is 24% (Linjama T. personal 
communication; Shah et al. 2011). Homozygosity has several implications. Firstly, 
homozygous patients become more broadly immunised because the number of 
structures that are foreign to the immune system is higher in blood transfusion, 
pregnancy and transplantation, as compared to heterozygous patients (Lucas, 
Leffell, Zachary 2015). Secondly, these patients regularly receive a full haplotype 
mismatched graft. Often, these patients are immunised against all non-self HLA. 
The most common Finnish haplotype is carried by 14% of the population, of which 
0.5% are homozygous carriers. Therefore, a donor homozygous for this haplotype 
is compatible with 14% of the entire waiting list of patients as there are no HLA 
mismatches with those patients. In some organ transplant programs, homozygous 
patients are given priority with regard to homozygous donors as these patients are 
prone to becoming immunised against foreign HLA (De Meester et al. 1998). 
However, there is high demand for these donors as they are compatible with many 
already immunised patients too. 
 
The broadness of HLA immunisation is measured with the PRA test. Traditionally 
this has been done with a cell panel representing as many HLA antigens as 
possible. The problem with these panels is that rare antigens are overrepresented 
while common antigens are underrepresented, therefore the results produced by 
the panel are not representative of the donor population. Today, many laboratories 
use calculated PRA, where the identified antibodies are correlated with the donor 
population, producing a more accurate result regarding the broadness of 
immunisation. Differences in the haplotype frequencies in various populations 
lead todifferences also in the probability of finding a donor for an individual patient 
from different countries through the international organ exchange (Glorie et al. 
2014). For most patients, this is not a problem, but for a patient with a PRA of 
nearly 100%, the chances of finding a donor from a certain population may be 
higher. For example, patient 30 in our study I had 1% probability of a HLA-
compatible Finnish donor and 0% of a Eurotransplant donor. The drawback of the 
calculated PRA is that the method used for antibody detection is much more 
sensitive than the PRA determined by a traditional cell panel, thus a larger 
proportion of immunised and highly immunised patients is seen when the 
calculated PRA is used (Cecka 2010). Therefore, the patient often has a much 





9.2 The value of DSA in histocompatibility testing 
 
The routine protocol for selecting patients to undergo a final crossmatch is based 
on ABO and HLA compatibility and clinical factors, such as the time on the waiting 
list, and immunisation level, with weighting of the variables varying depending on 
the allocation program (Chopra and Sureshkumar 2015; Mayer and Persijn 2006). 
According to the local selection criteria, one third of the patients were immunised 
at the time of the crossmatch. As negative virtual crossmatches are not required 
for a final crossmatch, about 25% of the patients were HLA-antibody incompatible 
because of DSA. Many patients selected for a crossmatch were broadly immunised 
and had antibodies against HLA antigens encoded by different HLA loci. 
Therefore, the risk of a positive virtual crossmatch for an immunised patient was 
70%. 
 
The ability of different crossmatch methods to detect DSA determined by a single 
antigen varies greatly, since these methods do not measure exactly the same thing. 
Only 53% of the serum samples containing DSA were positive with all three 
crossmatch methods, 74% were positive with two methods, and 94% with one 
method. The samples giving false positive crossmatches were predominantly 
different in each crossmatch method. Only one sample gave a false positive result 
with all the methods tested. However, 36% of the crossmatches where DSA were 
not present were false positives with at least one method. This lack of concordance 
in samples producing false negative and positive results with each of the 
crossmatch methods indicates that the difference in the results is based on the type 
of antibodies detected rather than the cut-off used for each technique. The highest 
false positive rate was seen for CDCXM (20%), while FCXM and LXM produced 
better results (10% and 11%, respectively). The high rate of false positives for 
CDCXM is in agreement with an earlier study where false positive rates of 18% 
and 23% were detected for T and B cells, respectively (Alheim et al. 2015). The 
DSA detection rate of 83% achieved with FCXM in our study was particularly good 
as the rates in previous studies have ranged from 52 to 65% (Reinsmoen et al. 
2016; Zachary et al. 2009b). The advantage of LXM is that it can distinguish 
between class I and class II DSA. The advantage offered by FCXM and LXM is that 
an objective measurement of fluorescence values by flow cytometer or bead 
analyzer is performed, instead of a subjective cytotoxicity reading by microscope. 
 
In our study, CDCXM had the lowest and FCXM the highest sensitivity, specificity 




antibodies. Does this mean that FCXM is the best method for crossmatching and 
the routinely used CDCXM should be replaced? This is a key question in the 
antibody compatibility and there are several issues that need to be discussed. First, 
what are the properties that make an antibody clinically relevant? Secondly, how 
do we identify it? Thirdly, how do we define what is clinically relevant. And finally, 
what are the goals of our crossmatch protocol? 
 
What properties do clinically relevant antibodies have? Most immunologists agree 
that their capacity for complement-mediated cytotoxicity is a crucial characteristic. 
On the other hand, pre-transplant IgM antibodies that are capable of cytotoxic 
killing are widely considered as clinically irrelevant (Taylor et al. 1989). The high 
rate of false positives found in our study for CDCXM is mostly explained by IgM 
antibodies, as DTT was not used in this study protocol to neutralize IgM 
antibodies. In our clinical transplant protocol, DTT treatment has been performed 
for samples of selected patients with known IgM antibodies for years. The current 
practice is to perform all CDCXM with DTT treated serum to gain the maximum 
benefit. Some IgG subgroups have higher potency for complement binding and they 
are therefore considered more relevant (Lefaucheur et al. 2016). IgG3 has been 
reported to be the most detrimental IgG subpopulation (Everly et al. 2014). The 
titer and affinity of an antibody are also of importance, but these are not commonly 
tested in clinical protocols due to the complexity of the assays. However, it has 
been shown that the affinity of an HLA antibody can have an effect on the level of 
complement-dependent cytotoxicity (Daga et al. 2017). 
 
Different antibody testing methods identify different types of antibodies. 
Complement-binding activity can be measured by CDC and with modified bead 
array. IgG antibodies can be measured with FCXM and LXM while specific HLA 
antibodies can be measured with bead array and LXM. Antibodies identified with 
CDCXM are regarded as clinically relevant. Somewhat less faith is placed in 
FCXM as this method has been suggested to be oversensitive, thus preventing 
transplants with good outcome (Vlad et al. 2009). There is also consensus that 
single antigen bead array identifies antibodies with very high sensitivity and thus 
some antibodies identified might not be clinically relevant (Aubert et al. 2009). 
 
In terms of clinical relevancy, we have several possible categories that may differ 
in their classification of antibodies. In an organ transplantation setting, there is 
an agreement that antibodies able to cause hyperacute rejection are clinically 




clinically relevant. How about antibodies predisposing to DGF, are they clinically 
relevant? 
 
We may see different clinical scenarios, depending on the type of exposure and 
antibody. A low titer antibody with a low MFI value may be able to promote chronic 
rejection. A high MFI antibody (if able to bind complement) might be able to 
promote hyperacute rejection. It has been shown that the incidence of acute AMR 
in patients with pretransplant DSA is higher than in patients without DSA (41.7% 
vs. 1.6%). Further, CDSA above 4300-5300 MFI is predictive of acute AMR and 
shorter 5-year graft survival (Salvade et al. 2016). 
 
An antibody that remains undetected in CDCXM but is detected by more sensitive 
methods, while unable to cause hyperacute rejection, could still cause DGF, as 
shown in study IV. In our adult study cohort, patients transplanted with a negative 
CDCXM crossmatch, and showing presence of DSA by the bead array, had a higher 
incidence of DGF. Later, another study has described similar findings with a 
higher DSA rate in patients with DGF (13 %) than in those without (6%) (P =0.03) 
(Willicombe et al. 2017). However, DSA was not associated with poor GFR, 
consistent with our study III with pediatric patients producing similar results. 
This finding has been confirmed later with adult patients, in whom no difference 
in the GFR was seen in DSA positive and negative patients (Zecher et al. 2017). 
This study, however, reported a significant difference in proteinuria levels between 
patients with and without DSA. 
 
Thus, HLA antibodies identified by the sensitive bead array are clinically relevant 
in some situations but not in all. The immunological state of a patient waiting for 
the first transplant is completely different from that of a patient already 
transplanted and under immunosuppression. It has been shown that the impact of 
DSA is greater in patients with a pre-activated immune system, as determined by 
elevated soluble CD30 levels (Susal et al. 2016). For patients with non-activated 
immune system, pre-transplant DSA status did not affect the 3-year graft survival, 
as DSA-positive and DSA-negative patients had graft survival rates of 83% and 
84%, respectively. However, patients with an activated immune system had 
significantly lower graft survival of 62% when DSA were present (Susal et al. 
2016). This finding shows that graft outcome is influenced by multiple 
immunological factors and DSA is just one of those. Interestingly, only 38% of the 
DSA-positive patients were found to have a pre-activated immune system, 




(Susal et al. 2016). The IgM DSA, regarded as irrelevant in the prospective 
crossmatch, may not be irrelevant if detected after transplantation. Persistent IgM 
DSA may be the first sign that the patient is inefficiently immunosuppressed 
(Everly et al. 2014). Also, class II antibody IgM to IgG isotype switching strongly 
correlates with cellular rejection and poor long-term outcome (Lietz et al. 2005). 
 
If we aim at hyper acute rejection-free transplantations, we can reach this goal 
with pre-transplant CDCXM. If we also want to perform an immunological risk 
assessment for each patient, a virtual crossmatch is needed. For a stable non-
immunised patient, a good match is preferable. However, for a patient with a 
homozygous or rare HLA, the goal might have to be set differently. For a patient 
with moderate immunisation, avoidance of antibody-incompatible transplants may 
give better outcome. For highly-immunised patients, a crossmatch-negative 
transplant, even with DSA, might be the target to aim for. 
 
Via pretransplant HLA antibody screening and identification, we can predict the 
crossmatch result to some extent. Most of our assays use donor cells as the target, 
and there is intra-individual variation in HLA expression and significant variation 
in HLA expression levels between different individuals, whichimpact the 
sensitivity of the crossmatch depending on donor factors (Badders et al. 2015; 






The estimation of the Finnish HLA haplotypes was performed with the phase 2.1 
software. The strong linkage disequilibrium and low recombination frequency in 
the HLA complex were taken into consideration in the settings of the analysis. As 
no haplotype phasing method performs with absolute certainty, some rare 
haplotypes may have been missed with the analysis. 
 
HLA antibody identification with the Luminex technique has several limitations. 
The amount of antigens on the beads varies and they are not present in natural 
proportions found on the cell surface. Therefore, different antibodies are identified 
with different sensitivities. Also, the number of beads is limited, thus the entire 
repertoire of possible antigens is not represented, possibly resultingin some 




antibodies and the natural complement present in the serum may block the 
secondary antibody used in the bead array, leading to false negative results. This 
can be prevented by adding EDTA, but this procedure was not yet in use when 
these studies were performed (Schnaidt et al. 2011). 
 
The donor material also brings some limitations as HLA expression varies between 
individuals. In CDCXM, one limitation is that in our study protocol, the total 
lymphocyte population from the spleen was used. There is also variation in T and 
B cell levels between the donors. Some donors have a higher number of B cells with 
higher HLA density, leading to variation in assay sensitivity. The lack of DTT 
treatment in the CDCXM raises the number of false positive results in our study. 
As CDCXM positive transplantations were not performed it was not possible to 
analyse the clinical relevance of DSA-negative CDCXM-positive results. 
 
Due to the study’s retrospective nature and the lack of pre-transplant serum 
samples in our study III, we were unable to perform survey of de novo DSA. The 
detailed evaluation of the relevance of DSA with our routine samples was 
challenging as many samples showed multiple DSA. 
 
 
9.4 Future perspectives 
 
As immunosuppression may not resolve all immunological incompatibilities 
between recipients and their donors, further studies are needed to understand the 
correlation between different factors and the transplant outcome. Today, we try to 
predict the outcome of the transplant with a very limited number of assays. In the 
future, understanding the synergistic effect of different factors may help us to 
evaluate better the immunological risk of an individual patient and to improve the 
overall graft survival. Most importantly, we may be able to perform individual pre-
transplant risk assessments for each patient based on urgency, rarity of the HLA 
type, and activity of the immune system, and with improved understanding of HLA 
antibody compatibility. Also, understanding the synergistic effect of HLA 
antibodies and other factors may help us to follow transplants with higher efficacy 
and identify those for which damage is still treatable. There is room for further 
development in assays measuring HLA immunisation. Currently, we are only able 
to measure one antibody type at a time, which hampers the clinical use of these 




titer in an individual sample is possible, but, so far, not cost nor time-effective; 








On the basis of the present study the following conclusions can be drawn: 
 
 
1. The Finnish population has unique allele and haplotype frequencies. The 
population-specific calculated PRA provides an accurate estimate of 
immunisation against the local donor population. As calculated PRA is based 
on a very sensitive bead array, the number of highly immunised patients will 
rise with this approach and some adjustments to the current definition of highly 
immunised patient is needed.  
 
2. The predictive value of antibody screening results from different crossmatch 
methods varies. The best accuracy was reached with FCXM. The differences 
seen for samples producing false negative and positive results in each 
crossmatch method indicates that the difference in the results stems from the 
type of antibodies detected rather than the cut-off used for each technique.  
 
3. HLA antibodies are common in pediatric kidney transplant patients, but they 
do not correlate with graft function measured by GFR. 
 
4. Pre-transplant DSA in CDCXM-negative adult kidney transplant recipients is 
associated with DGF. Patients with DSA have twice as high risk for DGF than 
patients without DSA. Third-party antibodies had no effect on the risk for DGF. 
The strength of DSA as measured by cumulative DSA MFI provided a good 
predictive value. The incidence of DGF was more than twice as high in patients 
with DSA of 3000–5000 MFI when compared to patients with DSA of 1000-3000 
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